HF
APEN

HRT Financial’s Apollo Endosurgery, Inc. APEN Stock Holding History

HRT Financial’s Portfolio APEN Stock Details APEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80,598
Closed -$803K – 3495
2022
Q4 		$803K Buy
+80,598
New +$601K 0.01% 1092
2022
Q3 		– Sell
-18,538
Closed -$67K – 3769
2022
Q2 		$67K Buy
+18,538
New +$87.6K ﹤0.01% 2483

Other funds holding APEN

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

HRT Financial's APEN Position: Q1 2023 in Review

HRT Financial sold out of Apollo Endosurgery, Inc. (APEN) in Q1 2023, closing a stake of 80,598 shares — an estimated $803K sold.

HRT Financial first reported a position in APEN in Q2 2022 and held it in 2 quarters. The position peaked at $803K in Q4 2022. 89 funds tracked by Wall St. Rank hold APEN as of Q1 2023.

  • HRT Financial reported no remaining Apollo Endosurgery, Inc. position as of Q1 2023 after selling out during the quarter.
  • HRT Financial sold 80,598 Apollo Endosurgery, Inc. shares in Q1 2023, an estimated $803K.
  • HRT Financial first reported a position in Apollo Endosurgery, Inc. in Q2 2022 and held it in 2 quarters.
  • HRT Financial's Apollo Endosurgery, Inc. position peaked at $803K in Q4 2022.
  • 89 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.